Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 12
2004 11
2005 7
2006 10
2007 14
2008 12
2009 24
2010 9
2011 15
2012 20
2013 17
2014 16
2015 12
2016 10
2017 16
2018 10
2019 10
2020 12
2021 19
2022 16
2023 13
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Results by year

Filters applied: . Clear all
Page 1
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Feng Y, Lee J, Yang L, Hilton MB, Morris K, Seaman S, Edupuganti VVSR, Hsu KS, Dower C, Yu G, So D, Bajgain P, Zhu Z, Dimitrov DS, Patel NL, Robinson CM, Difilippantonio S, Dyba M, Corbel A, Basuli F, Swenson RE, Kalen JD, Suthe SR, Hussain M, Italia JS, Souders CA, Gao L, Schnermann MJ, St Croix B. Feng Y, et al. Among authors: dimitrov ds. Cell Rep. 2023 Dec 26;42(12):113503. doi: 10.1016/j.celrep.2023.113503. Epub 2023 Nov 28. Cell Rep. 2023. PMID: 38019654 Free PMC article.
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL. Heitzeneder S, et al. Among authors: dimitrov ds. Cancer Cell. 2022 Jan 10;40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30. Cancer Cell. 2022. PMID: 34971569 Free PMC article.
Targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM. Yarmarkovich M, et al. Among authors: dimitrov ds. Nature. 2023 Nov;623(7988):820-827. doi: 10.1038/s41586-023-06706-0. Epub 2023 Nov 8. Nature. 2023. PMID: 37938771 Free PMC article.
Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies.
Si J, Shi X, Sun S, Zou B, Li Y, An D, Lin X, Gao Y, Long F, Pang B, Liu X, Liu T, Chi W, Chen L, Dimitrov DS, Sun Y, Du X, Yin W, Gao G, Min J, Wei L, Liao X. Si J, et al. Among authors: dimitrov ds. Cancer Cell. 2020 Oct 12;38(4):551-566.e11. doi: 10.1016/j.ccell.2020.08.001. Epub 2020 Aug 28. Cancer Cell. 2020. PMID: 32860752 Free article.
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL. Fry TJ, et al. Among authors: dimitrov ds. Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20. Nat Med. 2018. PMID: 29155426 Free PMC article. Clinical Trial.
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL. Majzner RG, et al. Among authors: dimitrov ds. Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. doi: 10.1158/1078-0432.CCR-18-0432. Epub 2019 Jan 17. Clin Cancer Res. 2019. PMID: 30655315 Free PMC article.
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris K, Szot C, Morris H, Swing DA, Tessarollo L, Smith SW, Degrado S, Borkin D, Jain N, Scheiermann J, Feng Y, Wang Y, Li J, Welsch D, DeCrescenzo G, Chaudhary A, Zudaire E, Klarmann KD, Keller JR, Dimitrov DS, St Croix B. Seaman S, et al. Among authors: dimitrov ds. Cancer Cell. 2017 Apr 10;31(4):501-515.e8. doi: 10.1016/j.ccell.2017.03.005. Cancer Cell. 2017. PMID: 28399408 Free PMC article.
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J. Tian M, et al. Among authors: dimitrov ds. Cell Rep Med. 2023 Oct 17;4(10):101212. doi: 10.1016/j.xcrm.2023.101212. Epub 2023 Sep 28. Cell Rep Med. 2023. PMID: 37774704 Free PMC article.
278 results